Voriconazole의 약물사용 평가
Drug Use Evaluation of Voriconazole
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Voriconazole is a novel wide-spectrum triazole antifungal agent active against Aspergillus, Candida, Fusarium, and Scedosporium, both in vitro and in clinical infections. This study was performed to evaluate the use of voriconazole by the criteria modified from IDSA and manufacturer’s guideline and conducted through retrospective chart review of fifty seven inpatients who received voriconazole in Seoul National University Hospital from January 2006 to June 2008. The justification of use showed high appropriate rate (87.8%). In analysis of critical indicators,the appropriateness of initial and maintenance dosage of voriconazole accounted for 87.7% and 91.0%. Duration of therapy was proved to be appropriate for 46.7% of patients. Rigorous attempts to correct potassium, magnesium, and calcium were made for 52.8% before starting voriconazole. Liver function tests were evaluated at the start of and during the course of voriconazole therapy for 56.1% and 86%. There is no coadministration of voriconazole with rifampicin, ritonavir, carbamazepine, or Phenobarbital. The complications occurred in 24 cases including hepatotoxicity(10 cases), visual disturbances(8 cases), nausea(2 cases), drowsy mentality(2 case), tachycardia(1 case), skin rash(1case) and cough(1 case). At the end of voriconazole therapy, there were successful outcome in 52.8% of the patients. The survival rate was 65%.
Abstract
Voriconazole is a novel wide-spectrum triazole antifungal agent active against Aspergillus, Candida, Fusarium, and Scedosporium, both in vitro and in clinical infections. This study was performed to evaluate the use of voriconazole by the criteria modified from IDSA and manufacturer’s guideline and conducted through retrospective chart review of fifty seven inpatients who received voriconazole in Seoul National University Hospital from January 2006 to June 2008. The justification of use showed high appropriate rate (87.8%). In analysis of critical indicators,the appropriateness of initial and maintenance dosage of voriconazole accounted for 87.7% and 91.0%. Duration of therapy was proved to be appropriate for 46.7% of patients. Rigorous attempts to correct potassium, magnesium, and calcium were made for 52.8% before starting voriconazole. Liver function tests were evaluated at the start of and during the course of voriconazole therapy for 56.1% and 86%. There is no coadministration of voriconazole with rifampicin, ritonavir, carbamazepine, or Phenobarbital. The complications occurred in 24 cases including hepatotoxicity(10 cases), visual disturbances(8 cases), nausea(2 cases), drowsy mentality(2 case), tachycardia(1 case), skin rash(1case) and cough(1 case). At the end of voriconazole therapy, there were successful outcome in 52.8% of the patients. The survival rate was 65%.
참고문헌 (8)
- "Pfizer. VFEND IV (voriconazole) forinjection, VFEND tablets, VFEND fororal suspension", ~ (2008)
- R?ping, M.J.G.T, "Patients at high risk ofinvasive fungal infections. When and howto treat", Drugs, 68(14), pp.1941~1962 (2008)
- Campenhout, H, "Voriconazoletreatment of invasive aspergillosis. Realworldversus health-economic modelresults", Clin Drug Invest, 28(8), pp.509~521 (2008)
- Herbrecht R, "Voriconazole versus amphotericin B forprimary therapy of invasive aspergillosis", N Engl J Med, 347(6), pp.408~415 (2002)
- Walsh, T.J., "Treatment of Aspergillosis: ClinicalPractice Guidelines of the InfectiousDiseases Society of America", Clin InfectDis, 46, pp.327~360 (2008)
- Stevens, D. A., "Practice guidelines for diseases caused byAspergillus", Clin Infect Dis, 30, pp.696~709 (2000)
- Alkan, Y, "Voriconazole-induced QT interval prolongationand ventricular tachycardia: Anon-concentration-dependent adverseeffect", Clin Infect Dis, 39, pp.49~52 (2004)
- Philips, J.A., "Torsades de pointes associated withvoriconazole use", Transpl Infect Dis, 9, pp.33~36 (2007)